Dr. Michael McCarthy
Head of the Vaccine Platform Group in ID/Vaccines
Dr. Michael McCarthy joined MedImmune in 1995, initially working on several vaccine initiatives (Lyme disease, parvovirus, uropathogenic E. coli). His primary contributions were to the HPV VLP program, where he developed the disassembly-reassembly process now used for commercial production of Gardasil and Cervarix. He has managed antiviral and antibacterial programs using either small molecule or antibody platforms. He recently was named head of the Vaccine Platform Group, which is progressing multiple pre-clinical/clinical stage prophylactic and therapeutic vaccine programs at the corporate headquarters in Gaithersburg, MD. He received his PhD in Biology from Wesleyan University in 1983, and worked as a post-doc at UCSF in the Dept. of Biochemistry and Biophysics.